about
Recent advances in understanding antitumor immunityThe Immunoregulatory Potential of Particle Radiation in Cancer Therapy.Advances in Immunotherapy for Melanoma: A Comprehensive Review.Bioengineering solutions for manufacturing challenges in CAR T cells.Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.Potential applications of nanoparticles in cancer immunotherapy.Immune modulation by dendritic-cell-based cancer vaccines.Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancerRecent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues.An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells.mRNA vaccines - a new era in vaccinology.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.Melanoma: a prototype of cancer-testis antigen-expressing malignancies.Novel T-cell-based vaccines via arming polyclonal CD4+ T cells with antigen-specific exosomes.Trial watch: DNA-based vaccines for oncological indicationsThe Role of Toll-Like Receptor in Inflammation and Tumor ImmunityNovel EXO-T vaccine using polyclonal CD4 T cells armed with HER2-specific exosomes for HER2-positive breast cancerThe swinging pendulum of cancer immunotherapy personalization
P2860
Q28067217-2B080930-5E6F-40A9-94A1-33D39487C8A5Q37625801-FD315249-DF30-4846-B32B-04A9BFDC937FQ38636521-4924075D-B050-42A9-8C16-ED3C5B73F1C4Q38637370-49012D54-99CF-41D7-B09B-E58AB3F44B91Q38644355-C3F7E47B-F79F-4924-938A-2BC57CDE7FD8Q39015434-07A08026-29FC-40EA-96B1-043CC2F1A1B6Q39147683-3A635E1F-CDC1-4074-817E-2D5C27B1DA54Q41016369-BF921E92-BB1B-420A-8300-DF47007DB5E6Q47134263-6BF79C86-9984-4041-9ADF-7DB7EA3208E5Q47136511-9523FAD8-A6EE-441D-A109-D012F88F46D5Q47155614-6A4F8DC3-886B-4E42-BE10-8FD0DE32B68BQ47736893-BF6378A8-1378-43EE-A291-B483FFED00DBQ48337458-2B3F955F-8A01-4BC3-84BB-7E11BA0D66BBQ48483233-9F37861C-4A8F-4975-9534-41BB3AE1E7A0Q50070352-AB54A5E4-06E8-4EE7-9C8D-E5E8E11B1E4BQ53623298-E276F18A-4F0C-46A1-B6BE-B32D4EB1B055Q56893452-55C840BC-9D09-435C-B319-E05455BFDC11Q57170572-938BB17B-7FEE-4295-BA54-35A92A6A19B4Q58547842-AA128ADE-63FA-4189-A375-8C5C34E31CA0Q58924840-1CBEBD27-DDF5-40D2-90EC-6D757B639DB0
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Human Tumor Antigens and Cancer Immunotherapy.
@en
type
label
Human Tumor Antigens and Cancer Immunotherapy.
@en
prefLabel
Human Tumor Antigens and Cancer Immunotherapy.
@en
P2860
P921
P356
P1476
Human Tumor Antigens and Cancer Immunotherapy.
@en
P2093
Nathalie Vigneron
P2860
P304
P356
10.1155/2015/948501
P407
P5008
P577
2015-06-16T00:00:00Z